|
Clinical manifestations
|
MEFV mutation carriers (n = 11)
|
R202Q homozygotes (n = 10)
|
MEFV/R202Qhomo (n = 20)
|
Control (n = 76)
|
|---|
|
Reccurent febrile episodes
|
8 (72.7 %)*
|
8 (80 %)*
|
16 (80 %)**
|
31 (40.8 %)
|
|
Peritonitis
|
5 (45.5 %)**
|
3 (30 %)
|
8 (40 %)**
|
8 (10.5 %)
|
|
Fatigue/malaise
|
6 (54.5 %)**
|
4 (40 %)
|
10 (50 %)**
|
11 (14.5 %)
|
|
Diffuse abdominal pain
|
7 (63.6 %)*
|
6 (60 %)*
|
12 (60 %)**
|
21 (27.6 %)
|
|
Lymphadenopathy
|
3 (27.3 %)
|
7 (70 %)*
|
10 (50 %)
|
28 (36.8 %)
|
|
Oligoarthralgia
|
5 (45.5 %)
|
3 (30 %)
|
8 (40 %)
|
20 (26.3 %)
|
|
Myalgia
|
3 (27.3 %)
|
3 (30 %)
|
6 (30 %)
|
13 (17.1 %)
|
- Values are shown as n (%)
-
MEFV/R202Qhomo MEFV mutation carrier plus R202Q homozygotes group, Control N/N and R202Q/N. Data for 4 subjects in control group were missing
- *p < 0.05; **p ≤ 0.01 compared to control group
